Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease

Table 4

Change in nonmotor symptoms scale score between initial and follow-up visits .


Domain	Initial evaluation	Follow-up	value

Cardiovascular	0.46 ± 1.16	1.02 ± 2.14	0.142
Mild	0.30 ± 1.19	0.34 ± 0.74	0.852
Moderate	0.75 ± 1.16	1.25 ± 2.76	0.598
Severe	0.00	9.00	—
Sleep/fatigue	6.33 ± 8.65	8.19 ± 8.44	0.141
Mild	2.50 ± 4.65	4.23 ± 4.99	0.095
Moderate	11.75 ± 8.54	12.50 ± 7.65	0.795
Severe	28.00	25.00	—
Mood/cognition	9.46 ± 14.40	12.40 ± 17.80	0.172
Mild	2.65 ± 6.80	5.53 ± 10.35	0.104
Moderate	14.00 ± 6.98	15.62 ± 18.11	0.787
Severe	18.00	62.00	—
Perceptual problems/hallucinations	0.17 ± 0.67	0.77 ± 2.10	0.044
Mild	0.07 ± 0.39	0.23 ± 0.86	0.425
Moderate	0.62 ± 1.40	1.12 ± 1.88	0.487
Severe	0.00	11.00	—
Attention	3.26 ± 6.00	5.09 ± 7.64	0.156
Mild	2.26 ± 4.03	3.11 ± 4.70	0.438
Moderate	8.12 ± 11.46	7.25 ± 10.89	0.782
Severe	2.00	36.00	—
Gastrointestinal tract	4.76 ± 6.37	5.56 ± 7.76	0.232
Mild	3.24 ± 4.90	3.00 ± 6.05	0.803
Moderate	4.87 ± 5.33	8.50 ± 8.41	0.280
Severe	12.00	30.00	—
Urinary function	6.17 ± 9.06	8.65 ± 10.94	0.240
Mild	2.72 ± 5.19	4.20 ± 6.53	0.389
Moderate	10.75 ± 11.75	11.75 ± 12.38	0.884
Severe	12.00	36.00	—
Sexual function	2.11 ± 4.69	3.83 ± 7.81	0.298
Mild	0.96 ± 2.38	2.04 ± 5.76	0.370
Moderate	4.87 ± 8.64	6.75 ± 9.37	0.654
Severe	0.00	24.00	—
Miscellaneous	4.80 ± 6.56	6.63 ± 6.38	0.112
Mild	3.24 ± 5.23	5.84 ± 6.13	0.117
Moderate	5.12 ± 4.82	5.37 ± 6.09	0.932
Severe	2.00	21.00	—
Total score	38.2 ± 38.96	52.48 ± 50.38	0.043
Mild	19.32 ± 23.77	28.68 ± 23.06	0.089
Moderate	60.87 ± 33.22	70.12 ± 43.41	0.606
Severe	74.00	254.00	—

Mean ± standard deviation. Each nonmotor symptom scale domain was subclassified according to the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part I (Non-Motor Experiences of Daily Living) and cut-off values established by Martínez-Martín et al. [9].

Neuroscience Journal

Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson’s Disease

Table 4